...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology letters >Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells.
【24h】

Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells.

机译：CIK对K562 / ADR细胞多药耐药性逆转和ADR敏感性增加的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Leukemia is a leading cause of cancer-related mortality in children worldwide, and multidrug-resistance (MDR) is a main reason for tumor chemotherapy failure. The present study investigated the effects of ADR following incubation with cytokine-induced killer (CIK) cells on reversing MDR in K562/ADR cells. Mononuclear cells were isolated from the peripheral blood of healthy individuals and cultured in vitro in the presence of a combination of cytokines to generate CIK for K562/ADR cell treatment. A decreased level of P-glycoprotein expression and glutathione (GSH), an increased intracellular Rh-123 content, decreased mRNA and protein expression levels of MDR gene 1, MDR-associated protein 1, GSH S-transferase-π, B-cell lymphoma 2 and Survivin, and the decreased phosphorylation of AKT and the transcriptional activity of nuclear factor-κB and activator protein 1 were detected following ADR treatment in CIK co-cultured K562/ADR cells. Additionally, the level of ADR sensitivity and the apoptosis rate were increased in the CIK co-cultured K562/ADR cells. These results indicate that pre-treatment with CIK could reverse the MDR of K562/ADR cells, and that patients would be most likely to benefit from the combination of chemotherapy and CIK therapy.
机译：白血病是全世界儿童与癌症相关的死亡率的主要原因，而多药耐药性（MDR）是肿瘤化疗失败的主要原因。本研究调查了与细胞因子诱导的杀伤（CIK）细胞孵育后ADR对K562 / ADR细胞MDR逆转的影响。从健康个体的外周血中分离出单核细胞，并在细胞因子联合存在下进行体外培养，以生成用于K562 / ADR细胞治疗的CIK。 P-糖蛋白和谷胱甘肽（GSH）的水平降低，细胞内Rh-123含量升高，MDR基因1，MDR相关蛋白1，GSH S-转移酶-π，B细胞淋巴瘤的mRNA和蛋白表达水平降低在CIK共培养的K562 / ADR细胞中，经ADR处理后检测到AKT 2和Survivin，以及AKT磷酸化的降低和核因子κB和激活蛋白1的转录活性。另外，在CIK共培养的K562 / ADR细胞中，ADR敏感性水平和细胞凋亡率增加。这些结果表明，CIK预处理可以逆转K562 / ADR细胞的MDR，并且患者最有可能从化疗和CIK疗法的结合中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号